PsyMed is an investment company dedicated to revolutionizing mental and brain health by funding founders that are implementing innovative neuroscience and frontier technologies. The company focuses on areas such as Neurotech & BCI, Digital Health, Precision Psychiatry, Psychedelics & New Compounds, and Alternative Modalities. PsyMed's mission is to transform the mental and brain illness epidemic into a flourishing future, aligning healing, responsibility, and profitability. The company leverages Artificial Intelligence by employing advanced algorithms and machine learning to analyze vast data, enabling early detection, accurate diagnosis, and personalized treatment, as well as drug development. They also concentrate on Neurotech & Human Augmentation, where they establish a direct connection of technical components with the brain and nervous system to address mental health disorders and neurological diseases. PsyMed also invests in Digital Health, using mobile applications, wearables, and online platforms to enable remote access to mental health services and facilitate data-driven personalized care. They have a keen interest in Holistic Medicine, embracing the interconnection of biology, psychology, environment, and lifestyle to address root causes and promote overall well-being. PsyMed is also exploring Metabolic Psychiatry, which investigates the bidirectional relationship between metabolic processes and mental health and how diet, exercise, and gut microbiota can impact brain function and psychiatric disorders. PsyMed is at the forefront of investing in the development of Psychedelic Medicine and New Compounds. They are funding the research and development of psychedelics and novel compounds to treat conditions including depression, addiction, PTSD, and more. They have a diverse portfolio of investments including IPOs, drug development platforms, and digital therapeutics. PsyMed is committed to giving back to the community and donates 4.19% of their profit to psychedelic non-profits and indigenous communities.